anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Wiskott-Aldrich syndrome protein family verprolin-homologous domain-containing protein 3 (WAVE3) is reported as an oncogene regulating cell proliferation and motility in multiple malignancies, while its role in tongue squamous cell carcinoma (TSCC) remains unknown. This study aimed to explore the expression and mechanism of WAVE3 in TSCC. We enrolled 64 TSCC patients admitted between June 2013 and February 2014 and collected their cancerous and adjacent normal tissues to determine WAVE3 expression by immunohistochemistry. The correlation of WAVE3 expression with TSCC patients' pathological characteristics was analyzed. Then, a 7-year follow-up was conducted to observe the value of WAVE3 in evaluating patient outcomes. In addition, human TSCC SCC9, SCC25, and CAL27 cells were purchased and detected by Cell Counting Kit-8 (CCK-8), Transwell, and scratch-wound assays for their proliferation, invasion, and migration capacities, while real-time quantitative PCR (qRT-PCR) and Western blotting were utilized to quantify WAVE3 and epithelial-mesenchymal transition (EMT)-related protein expression, respectively. The most active cell lines were selected to be infected with lentiviral vectors that silenced WAVE3 (named WAVE3-sh group) and overexpressed WAVE3 cDNA (named WAVE3-OE group) to observe the impacts of interfering WAVE3 expression on TSCC cell biological behavior. The positive expression of WAVE3 in TSCC tissue was found to be obviously enhanced and predominantly located in the cytoplasm. In addition, close correlations were identified between WAVE3 and T staging, clinical staging, lymphatic metastasis, distant metastasis, and differentiation degree (P < 0.05). Increased WAVE3 expression predicted an elevated risk of death, as indicated by the follow-up analysis (P < 0.05). SCC9 was selected for subsequent experiments among various TSCC cell lines studied because it showed the most potent ability to proliferate, invade, and migrate (P < 0.05). Silencing WAVE3 expression in SCC9 cells decreased cell proliferation, invasion, migration, and EMT-related protein expression (P < 0.05), while increasing WAVE3 expression promoted SCC9 viability. WAVE3, which was highly expressed in TSCC, promoted EMT in tumor cells and accelerated their proliferation, invasion, and migration, which might provide a new theoretical basis for molecular targeted therapy of TSCC in the future.
The invention discloses rotaxane which is a novel intelligent medicament carrier. The carrier is rotaxane which generally has two stable states; conversion of rotaxane between the stable states is shuttling; the shuttling of rotaxane can increase the rate of membrane-crossing motion of a molecule. The invention aims to research the influence of the shuttling of rotaxane on the membrane-crossing motion from the micro level by combining molecular dynamics simulation and a free energy calculation method. The balance structures of the two stable states of rotaxane in water and a membrane are researched by the molecular dynamics simulation, and the structural characteristics of the balance structures are analyzed. On the basis of the balance structures, the relative stability of the stable states are quantitatively compared by the free energy calculation method, so that a theoretical foundation can be provided for proving that the shuttling of rotaxane promotes the membrane-crossing motion, and a specific theoretical explanation is provided. Furthermore, the influence of different structural constitutions of rotaxane on the membrane-crossing motion is researched, the cognition on the membrane-crossing motion of rotaxane is deepened, and a good theoretical foundation is provided for developing the rotaxane type medicament carrier.
FIELD: medicine, narcology. SUBSTANCE: method involves carrying out three-stage course of treatment of patients with chronic alcoholism. On the first stage the preparation PL-1 containing glucose, ascorbic acid, magnesium sulfate, calcium lactate, sodium pyruvate and thiamine bromide is administrated for 10-12 days. On the second stage patients intake Zeosorb - enterosorbent based on natural zeolite-containing tuffs of Shivyrtuisk's layer for 14-15 days. On the third stage treatment with the preparation PL-1 is carried out again for 10 days. Method ensures to get the stable remission in alcoholics. EFFECT: enhanced effectiveness of treatment. 2 tbl, 3 ex
PURPOSE:To obtain a stable nicorandil preparation for transcutaneous administration, by mixing nicorandil with a specific organic acid. CONSTITUTION:A stable nicorandil preparation for transcutaneous administration can be produced by adding >=0.1wt% one of more organic acids selected from fumaric acid, oxalic acid, salicylic acid, tartaric acid and glutaric acid to nicorandil [N-(2-hydroxyethyl)nicotinamide nitrate]. The preparation is used in the form of ointment, tape, etc. The carrier for the preparation is e.g. polyvinyl alkyl ether, polyurethane, polyester, polyamide, etc., and is compounded with tackifier, plasticizer, etc., if necessary. Nicorandil is a drug having coronary vasodilating action and coronary contraction suppressing action and useful as a remedy for stenocardia of various types and giving little effect to cardiac blood flow kinetics and cardiac function. EFFECT:It has especially improved moisture stability.
Two long-term open-label studies were conducted, involving a total of 2,028 patients with ESRD undergoing hemodialysis. Patients were randomized to receive FOSRENOL or alternative phosphate binders for up to six months in one study and two years in the other. The daily FOSRENOL doses, divided and taken with meals, ranged from 375 mg to 3,000 mg. Doses were titrated to reduce serum phosphate levels to a target level. The daily doses of the alternative therapy were based on current prescribing information or those commonly utilized. Both treatment groups had similar reductions in serum phosphate of about 1.8 mg/dL. Maintenance of reduction was observed for up to three years in patients treated with FOSRENOL in long-term, open-label extensions.

No effects of FOSRENOL on serum levels of 25-dihydroxy vitamin D3, vitamin A, vitamin B12, vitamin E, and vitamin K were observed in patients who were monitored for 6 months.

Paired bone biopsies (at baseline and at one or two years) in 69 patients randomized to either FOSRENOL or calcium carbonate in one study and 99 patients randomized to either FOSRENOL or alternative therapy in a second study showed no differences in the development of mineralization defects between the groups.

Vital status was known for over 2,000 patients, 97% of those participating in the clinical program during and after receiving treatment. The adjusted yearly mortality rate (rate/years of observation) for patients treated with FOSRENOL or alternative therapy was 6.6%.
We aimed to describe facial directional asymmetry (DA) in individuals with different manifestations of laterality. Due to the overlap between brain and face development, a relationship between the manifestation of brain laterality and DA is hypothesised. These findings could clarify the relationship between the brain and facial phenotype and help to plan facial or oral motor rehabilitation. The DA of 163 healthy individuals was assessed by two complementary 3D methods: landmark and polygonal surface analysis using colour-coded maps. Handedness was assessed using the Edinburgh Handedness Inventory, while chewing side and eye preferences were self-reported. The results showed a similar DA pattern regardless of sex and laterality (the right-sided protrusion of the forehead, nose, lips, and chin) and a slightly curved C-shape of the midline in landmark analysis. A relationship between lateralized behaviours and DA was found only in males, in females the DA pattern was more homogenous. Right-handed individuals and right-side chewers showed a protrusion of the right hemiface. Males, left-handed and left-side chewers, manifested a protrusion of the left lateral hemiface. We suggest that these specific differences in males may be due to their typically higher level of brain asymmetry. No apparent relationship was found between eyedness and DA.
FIELD: medicine, pharmacy. SUBSTANCE: invention relates to pharmaceutical compositions comprising positive modulator of nicotine receptor agonist and agonist of nicotine receptor wherein indicated positive modulator shows ability to enhance effectiveness of nicotine receptor agonist. Indicated composition is used for treatment of state associated with reduced transfer in nicotine receptor, in particular, in Alzheimer's disease, schizophrenia and others. Invention claims also method for identification of positive modulator of nicotine receptor agonist. Invention provides the enhancement of activity of nicotine receptor agonist. EFFECT: valuable medicinal properties of composition. 21 cl, 6 dwg, 5 ex
OBJECTIVE: Children with hemiplegic cerebral palsy (CP) are typically ambulant with high motor functioning levels but with gait asymmetry and a greater risk of instability and falling. Physiotherapy is considered the core part of CP rehabilitation due to the risk of neurosurgery and the side effects of drug interventions. Although growing evidence has looked at the effect of upper limb loading during walking in many populations, such interventions in children with CP remain unexplored yet. The purpose of this study was to investigate if loading the upper limbs with external weights could improve walking speed, trunk control, and balance in ambulatory children with hemiplegic CP.
PATIENTS AND METHODS: The following outcome measures were recorded at baseline and six weeks after the intervention: gait speed [10-Meter Walk Test (10 MWT)], trunk control [Trunk Control Measurement Scale (TCMS)], and balance [Pediatric Balance Scale (PBS)]. Multiple 2 (groups) x 2 (time-points) mixed analysis of variance models (ANOVAs) were used for analysis.
RESULTS: Both groups showed a significant improvement (p < 0.001) in 10 MWT, TCMS, and PBS scores post-intervention. However, the magnitude of change in the outcome measures was higher in the intervention group (10 MWT = 0.59 m/s, TCMS = 10.41, PBS = 9.35) compared to the control group (10 MWT = 0.37 m/s, TCMS = 6.43, PBS = 4.68).
CONCLUSIONS: This study demonstrated that although both control and intervention groups showed improvements in terms of gait speed, trunk control, and balance, the intervention group that had upper limb loading showed higher significant improvements.  Clinicaltrial.gov ID: NCT05444387.
Subjects will be equipped with a heart rate (HR) monitor and perform an interval exercise bout on a cycle ergometer. To warm up, subjects will cycle at a work rate associated with 50% HRmax for 10 minutes. Wattage will then increase and subjects will perform a 30-minute exercise bout at a HR that elicits 75%-80% of their measured HRmax. Work rate will be adjusted, if needed, to keep HR within this value. Subjects will be given a 5-minute cool-down period at a work rate associated with 50% HRmax. After the exercise, subjects will remain seated in the lab for 4 hours and their blood pressure will be measured every 10 minutes using the Oscar 2 with SphygmoCor ambulatory blood pressure system, and cardiac output will be measured with 10-second averages using the PhysioFlow.
Thromboembolic diseases including arterial and venous thrombosis are common causes of morbidity and mortality globally. Thrombosis frequently recurs and can also complicate many inflammatory conditions through the process of 'thrombo-inflammation,' as evidenced during the COVID-19 pandemic. Current candidate biomarkers for thrombosis prediction, such as D-dimer, have poor predictive efficacy. This limits our capacity to tailor anticoagulation duration individually and may expose lower risk individuals to undue bleeding risk. Global coagulation assays, such as the Overall Haemostatic Potential (OHP) assay, that investigate fibrin generation and fibrinolysis, may provide a more accurate and functional assessment of hypercoagulability. We present a review of fibrin's critical role as a central modulator of thrombotic risk. The results of our studies demonstrating the OHP assay as a predictive biomarker in venous thromboembolism, chronic renal disease, diabetes mellitus, post-thrombotic syndrome, and COVID-19 are discussed. As a comprehensive and global measurement of fibrin generation and fibrinolytic capacity, the OHP assay may be a valuable addition to future multi-modal predictive tools in thrombosis.
The invention belongs to the traditional Chinese medicinal preparation, and especially relates to a kidney nourishing, blood circulation stimulating and pyralysis removing pill. The formula of the pill comprises sixty-two traditional Chinese medicines including Radix Astragali, Radix Ginseng Rubra, processed Rhizoma Atractylodis Macrocephalae, Poria cocos, Dioscorea tokoro Makino, Panax Notoginseng, dragon's blood, Lycium Chinense, prepared rehmannia root, unprepared rehmannia root, fried Eucommia ulmoides, Cibotium barometz, Rhizoma Drynariae, processed Boswellia carteri, processed myrrh, processed Achyranthes bidentata, safflower, Incised Notopterygium, Radix Angelicae Pubescentis, Viscum coloratum (Kom.) Nakai, fried Cuscuta chinensis Lam. and the like. The making method of the pill comprises the following steps: weighing the traditional Chinese medicines by a balance, respectively packaging, co-grinding the traditional Chinese medicines, sieving by a 800-1000 mesh sieve, processing a same amount of high-quality honey on a fire to silk drawing, and uniformly mixing the processed honey with the above obtained powder according to 8-9g each pill or processing to the powder to prepare a capsule. The pill or the capsule can be taken by a yellow rice wine or boiled water 2-3 times each day. The pill has the efficacies of blood circulation stimulating, blood stasis dispersing, meridian warming, vein relaxing, kidney nourishing, du strengthening, spleen invigorating, dampness dispelling, muscle and tendon relaxing, bone reinforcing, wind and coldness dispelling, liver nourishing and muscle moistening, has substantial effects on rheumatoid arthritis, lumbar disc herniation, cervical spondylosis, hyperostosis, spondylitis and femoral head necrosis, and is simple to make.
Participants of both programs - RiSE and Health Education Program (HEP) - will meet weekly for 8 consecutive weeks for approximately 2 hours every week. Two booster sessions will occur one month and two months after completion of the interventions. Classes will meet synchronously over Zoom. RiSE classes will be facilitated by two trained clinical psychologists. Expert speakers will be hired to provide the HEP classes (e.g dietician, pharmacist). The investigators will vary the time of day for each 8- week program in order to meet the scheduling needs of participants. Cohorts of 9-12 participants each and sessions for the treatment and control group will be provided concurrently. Topics for the health education program (HEP) (attention-control) were selected so they would not confound the overall objectives of the RiSE program.
Gemigliptin 50mg qd added to ongoing Glimepiride as fix-dose combination. The subjects will take a total of 2 tablets, Gemigliptin/Glimepiride combination \& Placebo for Glimepiride.
AIM: Parkinson's disease (PD) tremor is associated with dysfunction in the basal ganglia (BG), cerebellum (CB), and sensorimotor networks (SMN). We investigated tremor-related static functional network connectivity (SFNC) and dynamic functional network connectivity (DFNC) in PD patients.
METHODS: We analyzed the resting-state functional MRI data of 21 tremor-dominant Parkinson's disease (TDPD) patients and 29 healthy controls. We compared DFNC and SFNC between the three networks and assessed their associations with tremor severity.
RESULTS: TDPD patients exhibited increased SFNC between the SMN and BG networks. In addition, they spent more mean dwell time (MDT) in state 2, characterized by sparse connections, and less MDT in state 4, indicating stronger connections. Furthermore, enhanced DFNC between the CB and SMN was observed in state 2. Notably, the MDT of state 2 was positively associated with tremor scores.
CONCLUSION: The enhanced dynamic connectivity between the CB and SMN in TDPD patients suggests a potential compensatory mechanism. However, the tendency to remain in a state of sparse connectivity may contribute to the severity of tremor symptoms.
Patients receive pembrolizumab IV over 30 minutes on day 1 of odd number cycles. Patients also receive BO-112 by intratumoral injection on day 1, 8, and 15 of cycle 1, and day 15 of subsequent cycles. Treatment repeats every 3 weeks for up to 17 cycles in the absence of disease progression or unacceptable toxicity.
This Phase I trial will be conducted as an open label trial in 15 healthy adults. All subjects will receive a specific intravenous dose of Aerucin. There are three study groups, each with a specific dose of Aerucin. Study Group 1 will receive 2.0 mg/ kg of Aerucin . Study Group 2 will receive 8.0 mg/kg of Aerucin . Study Group 3 will receive 20 mg/kg of Aerucin . The dose levels of Aerucin are selected for this study based on animal studies showing protection in an animal model and absence of adverse effects in toxicological studies. Groups will be enrolled sequentially.
Patients with suboptimal glycemic control could be better managed if these higher risk patients could be identified and effective interventions were then targeted towards them. However, most practice settings perform infrequent laboratory testing every 3 to 6 months, if not at longer intervals. Current models to predict change in glycemic control perform poorly and do not take into account the behaviors that occur between these intervals. In this study, we will compare different methods to use data on daily health behaviors collected by wearable devices to enhance risk prediction models. Adults with pre-diabetes will complete a series of surveys and baseline assessments and then will be randomly assigned to use a waist-worn or wrist-worn wearable device for 6 months. Measures of HbA1c and LDL will be obtained at baseline and at 6 months.
Participants will be given 0.5% timolol ophthalmic solution to use after migraine onset. Participants will put 2 drops of solution in each eye after migraine and then again 2 hours later.
SARS-COV and SARS-COV-2 share similar pathogenic pathways that interact with pathways of cellular cholesterol metabolism. Depletion of cholesterol from cell membranes reduced the infectivity of SARS-COV by 90%. Several studies reported that pantethine was able to reduce total cholesterol levels and total fatty acids synthesis but its anti-SARS COV-2 activity has never been investigated. The inventors now demonstrate that pantethine is highly effective in the control of SARS-COV-2 infections in vitro. In particular, the inventors show that the effect of pathethine on the inhibition of the replication of SARS-COV-2 is interested at the dose of 100 μM (inhibition is around 76%) and the most effective concentration is 1000 μM (inhibition is around 98%). Pantethine treatments were able to reduce significantly the expression of the viral Spike and Nucleocapsid proteins and the accessory proteins ORF6. Thus the present invention relates to the use of pantethine for the treatment of a SARS COV-2 infection.
The invention belongs to the technical field of traditional Chinese medicines and in particular provides a compress ointment matrix. The compress ointment matrix comprises the following raw materials in parts by weight: 70-100 parts of volcanic mud, 50-100 parts of beewax, 40-80 parts of plaster matrix, 30-50 parts of Vaseline and 15-22 parts of rosin. The invention further provides a hot compress ointment for treating arthralgia, wherein the hot compress ointment is composed of two parts, namely a compress ointment matrix and a traditional Chinese medicine part. The invention correspondingly provides a method for preparing the compress ointment matrix and the hot compress ointment for treating arthralgia. The compress ointment matrix provided by the invention can achieve the effects of nourishing human skin, improving the drug effect and not adhering to the skin while removing, can be easily cleaned and repeatedly heated and used and is sanitary. The hot compress ointment for treating arthralgia provided by the invention is good in arthralgia treatment curative effect, small in side effects and low in cost, and the arthralgia is difficult to reoccur.
FIELD: medicine, pharmacy. SUBSTANCE: invention relates to a pharmaceutical preparation based on peptides, namely - to pharmaceutical compositions based on L-glutamyl-L-tryptophan. A pharmaceutical composition has L-glutamyl-L-tryptophan monosodium salt and an aminoacetic acid taken at the definite ratio of components. Obtained drug shows good water solubility and can be used as an immunostimulating agent. EFFECT: improved property of the composition. 2 tbl, 8 dwg
Patients receive nab-paclitaxel IV over 30-40 minutes and gemcitabine IV over 30-40 minutes on days 1 and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo MRI or CT throughout the trial. Patients may optionally undergo blood sample collection at baseline and on study.
FIELD: medicine. ^ SUBSTANCE: invention relates to medicine, ophthalmology, and can be used in diagnostics and surgical treatment of vision organ diseases. In realisation of the method instruments, products of medicinal purpose and liquids introduced into eye are used heated to +37C. Open eyeball is irrigated from above with 0.9% of sodium chloride at temperature +37C continuously by means of dropper with frequency 12 drops per minute, and illuminated by yellow dispersed light with wavelength 570-590 nm. Light formation is provided by light filter. Light brightness is increased under control of visibility of selected eye structures to minimal value, ensuring their visibility. ^ EFFECT: method eliminates injury of retina by light and injury of conjunctiva by dehydration and cooling. ^ 1 ex
Patients receiving thoracic epidural anesthesia for thoracoscopic surgery. Standard regimen with 8-20 ml Ropivacaine 0,5% in the epidural catheter. Postopertive Ropivacaine 0,2% 6 ml/h via catheter were administered.
PURPOSE:To provide the titled antigen composed of the E-isomer of androgen, gestagen or corticoid having carboxyalkyloxyimino group at the 3-site, and capable of giving an antibody having high specificity and titer against the corresponding steroid. CONSTITUTION:A carboxyalkylimino group such as carboxymethylimino group is introduced into 3-site of androgen, gestagen or corticoid (hereinafter refereed to as steroid) by conventional method. The COOH group of the resultant steroid containing 3-carboxyalkyloxyimino group is protected, and the compound is separated into Z-isomer and E-isomer e.g. by the thin-layer chromatography, etc. The protecting group of the resultant E-isomer is removed to obtain the objective antigen. Said antigen is bonded with an antigenic protein containing free amino group, and a mammal is immunized with the resultant bonded compound to obtain the corresponding antibody.
Primary care physicians (PCPs) and their patients used the intervention (OARS) for 4 weeks. They completed 2 interviews to obtain their feedback on the acceptability and feasibility of using OARS in a primary care setting. Data for this cohort was collected between February 18, 2020, to May 25, 2020.